Highlights PeptiDream Inc.

Equities

4587

JP3836750004

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-30 am EDT			5-day change	1st Jan Change
2,022 ^JPY	+24.66%		+24.66%	+36.02%

Mar. 13	Certain Preferred Stock of RayzeBio, Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	CI
Mar. 13	Certain Stock Options of RayzeBio, Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PeptiDream to Partake in Bristol Myers' Tender Offer for All RayzeBio Shares	Feb. 15	MT
PeptiDream Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2024	Feb. 14	CI
PeptiDream Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 14	CI
PeptiDream Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	Nov. 09	CI
Peptidream Announces Update on PDL1 Program Partnered with Bristol-Myers Squibb Company	23-10-26	CI
PeptiDream Inc. Announces Collaboration and License Agreement with Genentech for the Discovery and Development of Novel Peptide- Radioisotope Drug Conjugates	23-09-19	CI
RayzeBio, Inc. has completed an IPO in the amount of $310.9968 million.	23-09-14	CI
PeptiDream Unit Pays 4 Billion Yen Contingent Consideration for AMYViD Indication Change; Shares Down 3%	23-09-10	MT
PeptiDream Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	23-08-09	CI
PeptiDream Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-09	CI
Astellas Pharma Inc. and PeptiDream Inc. Enter into Research Collaboration and License Agreement to Discover Novel Targeted Protein Degraders	23-07-25	CI
PeptiDream Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
PeptiDream Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2023	23-05-11	CI
PeptiDream Inc. Announces Nomination of Second Peptide Radiopharmaceutical Therapeutic Development Candidate	23-03-22	CI
Ono Enters into A Drug Discovery Collaboration Agreement with Peptidream to Discover and Develop Macrocyclic Constrained Peptide Therapeutics	23-03-13	CI
PeptiDream Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	23-02-14	CI
PeptiDream Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-14	CI
Eli Lilly Teams Up With Japan's PeptiDream for Discovery of New Peptide Drug Conjugates	22-12-27	MT
Merck, PeptiDream to Collaborate to Develop Peptide Drug Conjugates	22-12-27	MT
Peptidream Announces Collaboration and License Agreement with MSD for the Discovery and Development of Novel Peptide Drug Conjugates	22-12-27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights PeptiDream Inc.

Equities

4587

JP3836750004

Highlights

Filters